Catalyst Pharmaceuticals Q3 EPS $0.49 Beats $0.44 Estimate, Sales $102.69M Beat $100.38M Estimate
Portfolio Pulse from Benzinga Newsdesk
Catalyst Pharmaceuticals reported Q3 earnings of $0.49 per share, beating the analyst consensus estimate of $0.44 by 11.36%. This is an 88.46% increase from the same period last year. The company also reported quarterly sales of $102.69 million, beating the analyst consensus estimate of $100.38 million by 2.30%. This is a 79.39% increase from the same period last year.
November 08, 2023 | 9:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Catalyst Pharmaceuticals reported strong Q3 earnings and sales, both beating analyst estimates. This indicates a positive financial performance and could potentially lead to a short-term increase in the stock price.
Catalyst Pharmaceuticals reported a significant increase in both earnings and sales compared to the same period last year, and also beat analyst estimates. This strong financial performance is typically a positive signal to investors and can lead to increased demand for the stock, potentially driving up the price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100